ESTA

Interested in Establishment Labs Holdings Inc.? Here are five stocks we like better. Strong growth and raised outlook: Second-quarter revenue rose 31.7% year over year to $67.5 million, while adjusted EBITDA improved to positive $3.7 million from a loss of $8.5 million. Establishment Labs raised its full-year revenue forecast to $269 million–$271 million. U.S. and Minimally Invasive platforms drive momentum: U.S. revenue surged 140.9% to $24.7 million, with more than 100,000 Motiva implants sold and over 2,000 accounts. Mia and Preservé generated $12.1 million in quarterly revenue, while Preservé exceeded surgeon-training expectations and commands a significant pricing premium. Improving financial position and future pipeline: Gross margin increased to 70.6%, cash reached $71.2 million, and management said no future equity raises are needed to execute its strategy. The company expects to become free-cash-flow positive in the second half of 2026, while reconstruction revenue is expected from 2027 and GEM could contribute in the U.S. from 2028 or later. Establishment Labs (NASDAQ:ESTA) reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage. Revenue for the quarter totaled $67.5 million, while adjusted EBITDA was positive $3.7 million, compared with an adjusted EBITDA loss of $8.5 million in the prior-year period. The company raised its full-year revenue outlook to a range of $269 million to $271 million, from prior guidance of $266.5 million to $268.5 million. → 3 Drone Stocks That Should Soar After the Summer Slump CEO Peter Caldini said the company had started the third quarter well despite the period traditionally being the seasonal low point for breast augmentation procedures. Establishment Labs expects to transition to free-cash-flow positive in the second half of 2026 and to remain free-cash-flow positive for fiscal 2027. U.S. revenue increased 140.9% from a year earlier to $24.7 million, representing 36.6% of total company revenue, compared with 20% a year earlier. U.S. revenue also rose 26% sequentially from the first quarter, according to Caldini. → Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth The company said it surpassed 100,000 Motiva implants in the U.S. market less than 21 months after launch. It also ended the quarter with more than 2,000 U.S. accounts, with many accounts using Motiva across multiple surgeons. Caldini said growth is increasingly coming from greater use within existing accounts as surgeons become more familiar with the product’s clinical data, patient outcomes and differentiators. He added that management is seeing growing patient awareness of the Motiva brand, citing company feedback that 75% of surgeons report patients asking for an implant brand and, in 93% of those instances, the requested brand is Motiva. → Jersey Mike's Serves Fresh Gains After IPO Stumble Outside the U.S., revenue was $42.8 million, up 4.4% year over year. Europe grew 16%, led by Italy, Germany and the U.K., while Argentina continued its positive trajectory and Brazil remained stable, management said. Caldini said demand in most distributor markets remained steady, though Middle East orders were below historical levels amid regional conflict. CFO Sandra Harris said the Middle East accounts for less than 5% of company revenue. Establishment Labs generated $12.1 million in quarterly revenue from its Minimally Invasive platform, which includes the Mia and Preservé procedures. Management said the platform is approaching 15% of full-year global revenue and is performing above its original expectations. Mia is currently offered outside the U.S. and is intended for women seeking a more subtle enhancement. Preservé, which is being rolled out in the U.S., is designed to accommodate a broader range of patient needs, including larger augmentations and augmentation mastopexy procedures, while retaining the company’s tissue-preserving approach. Caldini said Preservé had more than 300 trained and certified surgeons at the end of the quarter, exceeding the company’s original full-year expectation by more than 50%. Establishment Labs now expects to train about 500 surgeons during 2026. Management said surgeons are generally charging 30% to 50% more for Preservé than for traditional breast augmentations. Caldini also said Preservé commands a premium of more than two times that of a traditional breast augmentation procedure for Establishment Labs in the U.S. The company said its research indicates that 15% of women undergoing Preservé had not initially been considering breast augmentation. Caldini said Minimally Invasive procedures can address barriers including anesthesia, scarring and recovery time, potentially attracting patients who may not otherwise have pursued augmentation. Gross profit was $47.7 million, or 70.6% of revenue, compared with a 68.8% gross margin in the prior-year quarter. Harris attributed the margin improvement to a greater contribution from higher-margin U.S. and direct international markets, favorable product mix and growth in the Minimally Invasive platform. Operating expenses were reported at $52 million for the quarter, including one-time costs, while management said expenses increased modestly relative to nearly 32% revenue growth. Harris said the company has been able to leverage operating spending and does not anticipate major increases beyond its prior investment levels as it advances its innovation pipeline. Cash and cash equivalents totaled $71.2 million at quarter-end, up $3.1 million from the first quarter and $16.5 million from a year earlier. Harris said the company generated positive overall cash flow and has sufficient liquidity to execute its strategy without future equity raises. For the third quarter, management cautioned that the business is subject to normal seasonal softness during summer vacation periods. The fourth quarter is expected to be the company’s strongest quarter of the year. Establishment Labs continues to advance its U.S. reconstruction submission with the Food and Drug Administration, expand its U.S. implant size matrix and develop GEM, a potential gluteal augmentation procedure. Caldini said the FDA has begun BIMO audits of clinical study sites for the reconstruction submission, while the company is responding to what it considers routine agency questions. Management does not expect material reconstruction revenue until 2027. The company said it expects revenue growth of around 25% in 2027, though it did not provide more detailed guidance for that year. For GEM, Caldini said Establishment Labs is conducting a clinical study in Costa Rica and expects an early experience in Latin America during the second half of 2027. The company is still evaluating regulatory pathways in the U.S. and Europe and does not expect GEM to contribute materially in the U.S. until 2028 or later. Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability. The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Establishment Labs Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

NEW YORK, August 06, 2026--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026. Second Quarter Highlights and Outlook (Unaudited) Revenue of $67.5 million, up 31.7% from Q2 2025, and sequential growth of 12.8% from Q1 2026 $24.7 million of sales in the United States, up 26% from Q1 2026 Guidance raised to $269 million to $271 million, an increase from previous guidance of $266.5 million to $268.5 million Minimally invasive revenue of $12.1 million for the quarter Gross margin of 70.6% compared to 68.8% in the year-ago period Loss from operations was $4.3 million compared to a loss of $14.1 million in the year-ago period Adjusted EBITDA income of $3.7 million compared to a loss of $8.5 million in the year-ago period Cash balance of $71.2 million as of June 30, 2026, a $16.5 million improvement from the year-ago period, and up $3.1 million from Q1 2026 "Momentum continued throughout the second quarter and into the third quarter as we continue to take market share and expand the category," said Peter Caldini, Chief Executive Officer. "Strong execution globally, accelerating adoption of our minimally invasive platform, and expanding profitability allows us to raise our full-year revenue guidance. We should have strong growth in the second half of 2026 and throughout 2027, as our business inflects to be both high growth and free cash flow positive." Second Quarter 2026 Financial Results (Unaudited) Total revenue for the quarter ended June 30, 2026 was $67.5 million, compared to $51.3 million for the same period in 2025, representing a growth of 31.7%, with Motiva USA revenue increasing to $24.7 million from $10.3 million in the prior-year period. Gross profit for the second quarter of $47.7 million, or 70.6% of revenue, increased compared to $35.3 million, or 68.8% of revenue, for the same period in 2025. The improvement in gross profit margin was primarily driven by favorable geographic and channel mix, including continued growth of our higher-margin U.S. business and our minimally invasive platform. Total operating expenses for the second quarter were $52.0 million compared to $49.4 million in the second quarter of 2025. Total operating expenses included one-time charges related to debt refinancing and restructuring costs of $2.2 million in the second quarter of 2026 and $0.5 million in the same period last year. Excluding these one-time charges, adjusted operating expenses increased 2.0% compared to a revenue growth of 31.7%, demonstrating the operating leverage we are achieving as the business continues to scale. Net loss for the second quarter was $11.7 million, compared to a net loss of $16.6 million in the year-ago period. Adjusted EBITDA increased by $12.2 million to an income of $3.7 million compared to a loss of $8.5 million in the year-ago period, achieving another quarter of positive adjusted EBITDA. The Company’s cash balance on June 30, 2026 was $71.2 million. Conference Call and Webcast Information Establishment Labs will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss its financial results. To participate in the conference call, Dial: (+1) 888-396-8049 (US & Canada) / (+1) 416-764-8646 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zen™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "intends to," "would," "will," "may" or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company's annual report on Form 10-K filed on February 27, 2026, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends. ESTABLISHMENT LABS HOLDINGS INC.Reconciliation of EBITDA and Adjusted EBITDA(In thousands)(Unaudited) Non-GAAP Financial Measures To supplement our financial results presented in accordance with GAAP, this release includes the following measures defined by the Securities and Exchange Commission as non-GAAP financial measures: EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies, limiting the usefulness of the measures for comparison with other companies. EBITDA is defined as net income or loss excluding: (1) interest income and expense; (2) provision for income taxes; and (3) depreciation and amortization. We consider EBITDA useful to an investor in evaluating and facilitating comparisons of our operating performance between periods by removing the impact of our capital structure (primarily interest expense) and asset base (primarily depreciation and amortization) from our operating results. We also present Adjusted EBITDA which includes additional adjustments for items such as other non-cash charges, gains or losses on extinguishment of debt, share-based compensation, debt refinancing costs, foreign currency gains and losses and restructuring costs. We believe that Adjusted EBITDA provides useful supplemental information to investors regarding our ongoing operating performance that, when considered with net income and EBITDA, is beneficial to an investor's understanding of our performance. We believe disclosure of this information is also useful to investors as it provides insight into the earnings that management uses to make strategic decisions. These non-GAAP financial measures should be considered along with, but not as alternatives to, net income or loss as prescribed by GAAP as a measure of our operating performance. EBITDA and Adjusted EBITDA do not represent cash generated from operating activities under GAAP and should not be considered as alternatives to cash flows from operations or any other operating performance measure prescribed by GAAP. These measures are not measures of our liquidity, nor are indicative of funds available to fund our cash needs. These measurements do not reflect cash expenditures for long-term assets and other items that have been and will be incurred. EBITDA and Adjusted EBITDA may include funds that may not be available for management’s discretionary use due to functional requirements to conserve funds for capital expenditures, property acquisitions, and other commitments and uncertainties. Please see "Reconciliation of EBITDA and Adjusted EBITDA" for a reconciliation of these measures to net income (loss), the most directly comparable financial measure. This release also includes information about our expectations regarding Adjusted EBITDA on a forward-looking basis. We have not provided a reconciliation of such forward-looking Adjusted EBITDA information because a reconciliation of such measure to our expected GAAP net income (loss) on a forward-looking basis is not available without unreasonable efforts. The timing or amount of various reconciling items that would impact the forward-looking expectations for this non-GAAP financial measure are uncertain, depend on various factors and cannot be reasonably predicted. Such unavailable information could be material to our results computed in accordance with U.S. GAAP. The following is a reconciliation of net loss to EBITDA and Adjusted EBITDA: View source version on businesswire.com: https://www.businesswire.com/news/home/20260806794312/en/ Contacts Investor/Media Contact: Malavika [email protected]

This article first appeared on GuruFocus. Revenue: $67.5 million, up 31.7% year-over-year. U.S. Revenue: $24.7 million, up 140.9% year-over-year, representing 36.6% of total revenue. OUS Revenue: $42.8 million, up 4.4% year-over-year. Minimally Invasive Platform Revenue: $12.1 million in the quarter. Gross Margin: 70.6% of revenue, up from 68.8% in the prior year period. Operating Expenses: $52 million for the quarter. Adjusted EBITDA: Income of $3.7 million, an improvement of $12.2 million from a loss of $8.5 million in the prior year period. Cash and Cash Equivalents: $71.2 million, a sequential increase of $3.1 million from Q1. Full Year Revenue Guidance: Raised to $269 million-$271 million, up from the previous range of $266.5 million-$268.5 million. Warning! GuruFocus has detected 5 Warning Sign with ESTA. Is ESTA fairly valued? Test your thesis with our free DCF calculator. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Revenue grew 31.7% year-over-year to $67.5 million, with U.S. sales surging 140.9% to $24.7 million. Adjusted EBITDA turned positive at $3.7 million, a $12.2 million improvement from the prior year. Minimally invasive platform (Mia and Preserve) generated $12.1 million in revenue, approaching 15% of global sales and expanding the total addressable market. Surpassed 100,000 Motiva implants in the U.S. in under 21 months, with over 2,000 accounts and 75% of surgeons reporting patient brand requests. Raised full-year revenue guidance to $269-$271 million and expect to be free cash flow positive in the second half of 2026. Preserve surgeon training exceeded expectations (300+ certified, targeting 500 for the year), with procedures commanding 30-50% premium pricing. Strong OUS performance in direct markets, especially Europe (16% growth), with diversified revenue reducing exposure to volatile regions. OUS revenue growth was only 4.4%, impacted by the Middle East conflict, which has reduced orders and is expected to remain weak for the rest of the year. Third quarter is expected to be seasonally weak, with summer vacations affecting both U.S. and OUS sales. Reconstruction revenue is not expected to be material until 2027, with FDA approval timing still uncertain. Operating expenses, including one-time refinancing costs, reached $52 million, though adjusted for these, growth was modest. The company faces ongoing macroeconomic and geopolitical uncertainty across several regions, which could impact future demand. GEM, the gluteal augmentation product, is not expected to contribute to U.S. revenue until 2028, limiting near-term growth catalysts. Cash position remains relatively low at $71.2 million, though management states it is sufficient without future equity raises. Q: Can you provide more details on the development and regulatory timeline for GEM, the company's gluteal augmentation procedure?A: Peter Caldini (CEO) stated that GEM leverages the Minimally Invasive platform technology to offer a safer, more predictable alternative to the traditional Brazilian butt lift. The company is currently conducting a clinical study in Costa Rica and expects an early experience launch in Latin America in the back half of next year. They are working through the regulatory pathway for the U.S. and Europe, but do not see GEM as a contributor in the U.S. until 2028 and beyond. Q: What is the current status of the FDA submission for the breast reconstruction indication, and what is the expected timeline for approval and revenue contribution?A: Peter Caldini (CEO) confirmed they have received feedback from the FDA and are responding to routine questions. The FDA has initiated BIMO audits of clinical study sites, which is a positive sign of progress. While the approval timing is up to the FDA, the company does not expect to achieve material revenue from reconstruction until 2027. This indication doubles their total addressable market in the U.S. Q: How is the adoption and utilization of the Preserve procedure progressing in the U.S., and what are the expectations for the back half of the year?A: Peter Caldini (CEO) reported that over 300 surgeons are now trained and certified on Preserve, which is more than 50% above original expectations. The company is expanding training capacity and now targets approximately 500 trained surgeons for the full year 2026. Adoption is quick following certification, and they expect Preserve to be a key growth driver in the second half of the year. Q: What is the financial outlook for the Minimally Invasive platform, and how should we think about its contribution for the full year?A: Cassandra Harris (CFO) stated that the Minimally Invasive platform generated $12.1 million in revenue in Q2 and is performing ahead of expectations. The company previously guided to over $35 million for the year, but now expects the platform to approach approximately 15% of total company revenue for the full year, which is a higher contribution than originally anticipated. Q: Can you provide color on the company's expectations for the second half of 2026 and any preliminary thoughts on 2027?A: Peter Caldini (CEO) expects the strong momentum from the first half to continue, particularly in the U.S. and direct markets. Cassandra Harris (CFO) reminded investors of normal seasonality, with Q4 expected to be the strongest quarter. The company raised full-year revenue guidance to $269-$271 million. For 2027, the only information provided to date is an expectation for revenue growth of around 25%. Q: How is the competitive dynamic playing out for Preserve, and what is the pricing premium compared to traditional breast augmentation?A: Peter Caldini (CEO) explained that Preserve provides surgeons with a significant competitive advantage by bringing new patients into the category. Market research shows that 15% of women who had Preserve were not initially considering breast augmentation. Surgeons are charging 30%-50% more for Preserve procedures than traditional augmentations, and in the U.S., it commands a premium of more than two times that of a traditional procedure. Q: What is driving the growth outside the U.S., and how is the company managing exposure to volatile markets like the Middle East?A: Peter Caldini (CEO) highlighted that OUS growth of 4.4% was driven by strong performance in direct markets, particularly Europe, which grew 16% with strength in Italy, Germany, and the U.K. The company is de-emphasizing its dependency on distributors. While demand in most distributor markets was steady, the Middle East was an outlier due to the conflict, with orders at much lower levels. Cassandra Harris (CFO) noted that the Middle East represents less than 5% of total revenue. Q: How should investors think about the trajectory of operating expenses given the investments in the Minimally Invasive platform, reconstruction, and GEM?A: Cassandra Harris (CFO) stated that the company is leveraging its operating expenses, with single-digit growth in opex against strong double-digit revenue growth. Excluding one-time refinancing costs, operating expenses were well controlled. The company is pacing its R&D investments appropriately for the innovation pipeline and does not anticipate any major increases to previous spending levels, while continuing to look for areas of leverage. Q: If reconstruction approval were received on January 1, how quickly would it contribute to revenue, and does the 25% growth expectation for 2027 include a significant contribution from reconstruction?A: Cassandra Harris (CFO) explained that the reconstruction launch would not grow as rapidly as the Minimally Invasive platform launch, as it takes longer to work with hospitals. There is no anticipation of reconstruction revenue in 2026. The company will provide more color on the 2027 contribution once there is more clarity on FDA timing. Q: What is the impact of the Mia procedure on the market, and how is it driving the strategy for the Minimally Invasive platform?A: Peter Caldini (CEO) stated that Mia, available outside the U.S., is a key driver for the development of Preserve and the entire Minimally Invasive platform. It addresses key barriers preventing women from undergoing breast augmentation, such as minimal anesthesia, smaller scars, and quicker recovery. The platform is bringing new patients into the category and is expected to become an increasingly important growth driver in the years ahead. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

NEW YORK, July 23, 2026--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results. To participate in the conference call, Dial: (+1) 888-396-8049 (US & Canada) / (+1) 416-764-8646 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "intends to," "would," "will," "may" or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company's annual report on Form 10-K filed on February 27, 2026, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends. View source version on businesswire.com: https://www.businesswire.com/news/home/20260723502579/en/ Contacts Investor/Media Contact:Malavika [email protected]

On May 6, 2026, Founder and former CEO Juan José Chacón Quirós, now serving as a director and paid consultant, reported the indirect sale of 105,000 shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) for a total of approximately $7.92 million, according to a SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average purchase price ($75.42); post-transaction value based on May 6, 2026 market close price ($74.54). What portion of the insider’s total position was impacted by this sale? This sale represented 9.74% of Chacon Quiros’s combined direct and indirect holdings, or 10.17% of the indirect position managed through Sariel Group Ltd, with no direct shares traded in this event. What is the ownership structure and how does the indirect nature of this sale affect control? The 105,000 shares were held indirectly through Sariel Group Ltd; although Chacon Quiros has voting and dispositive power, he disclaims beneficial ownership except for his pecuniary interest, which is typical for entity-structured insider holdings. How does this transaction compare to the insider’s historical trading cadence and capacity? The 105,000-share sale is the largest single sale by Chacon Quiros to date. With a large block of direct shares transferred into Sariel Group in March 2026, the pool available for future direct-share transactions is considerably smaller than it was a year ago, meaning future sale sizes are increasingly constrained by available capacity rather than discretionary moderation. What does the conclusion of the 10b5-1 plan mean for future trading activity? With all shares subject to the December 2025 10b5-1 plan now sold, any future activity would require adoption of a new plan or be subject to open-market trading windows, potentially reducing the predictability of sale cadence going forward. * 1-year performance calculated using May 9th, 2026 as the reference date. Offers silicone gel-filled breast implants (Motiva Implants, Motiva Ergonomix, Motiva Ergonomix2), Motiva Flora Tissue Expander, and distributes Puregraft products for autologous adipose tissue harvesting. Generates revenue primarily through the manufacturing and direct or distributor-based sales of medical devices for aesthetic and reconstructive plastic surgery. Serves plastic surgeons and healthcare providers in Europe, Latin America, the Asia-Pacific, and other international markets. Establishment Labs Holdings Inc. is a global medical technology company specializing in advanced breast implant solutions and related surgical devices. The company leverages proprietary product designs and a diversified international distribution network to address the needs of plastic and reconstructive surgeons. Its focus on innovation and international market access underpins its competitive position in the medical devices sector. This sale was pre-scheduled under a 10b5-1 plan adopted in December 2025, so the timing — which landed on the same day as Q1 earnings — is coincidental, not a read on results. Chacon Quiros is the founder and former CEO who stepped down in early 2025 and now serves as a paid consultant and board director, with nearly 973,000 shares still held between his entity and direct stake. The more relevant numbers are in the Q1 release: US revenue hit $19.6 million, up 13.3% from Q4 2025, and the company posted its third consecutive quarter of positive adjusted EBITDA. Full-year guidance was raised and management is targeting free cash flow positive in the second half of 2026. A reconstruction approval application is pending on top of the existing augmentation clearance. If you're evaluating ESTA, the question isn't what the founder did with a pre-scheduled slice of his position — it's whether the US ramp sustains and whether the reconstruction approval adds a second growth leg. Those are the variables worth tracking before making a position decision. Before you buy stock in Establishment Labs, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Establishment Labs wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!* Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 11, 2026. Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. ESTA Founder Sells $7.9M on Earnings Day — Here's Why that's Not the Story was originally published by The Motley Fool

It's been a good week for Establishment Labs Holdings Inc. (NASDAQ:ESTA) shareholders, because the company has just released its latest quarterly results, and the shares gained 5.0% to US$72.03. The results don't look great, especially considering that statutory losses grew 27% toUS$0.45 per share. Revenues of US$60m did beat expectations by 4.3%, but it looks like a bit of a cold comfort. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Establishment Labs Holdings after the latest results. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the nine analysts covering Establishment Labs Holdings are now predicting revenues of US$267.4m in 2026. If met, this would reflect a decent 16% improvement in revenue compared to the last 12 months. Losses are supposed to decline, shrinking 15% from last year to US$1.27. Before this latest report, the consensus had been expecting revenues of US$265.2m and US$1.10 per share in losses. So it's pretty clear the analysts have mixed opinions on Establishment Labs Holdings even after this update; although they reconfirmed their revenue numbers, it came at the cost of a notable increase in per-share losses. View our latest analysis for Establishment Labs Holdings The consensus price target held steady at US$89.89, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Establishment Labs Holdings, with the most bullish analyst valuing it at US$100.00 and the most bearish at US$76.00 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Establishment Labs Holdings is an easy business to forecast or the the analysts are all using similar assumptions. Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Establishment Labs Holdings' rate of growth is expected to accelerate meaningfully, with the forecast 23% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 11% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.0% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Establishment Labs Holdings to grow faster than the wider industry. The most important thing to take away is that the analysts increased their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Establishment Labs Holdings analysts - going out to 2028, and you can see them free on our platform here. Before you take the next step you should know about the 1 warning sign for Establishment Labs Holdings that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

This article first appeared on GuruFocus. Release Date: May 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Establishment Labs Holdings Inc (NASDAQ:ESTA) reported a strong start to 2026 with $59.9 million in revenue, marking a 45% growth over Q1 2025. The U.S. business showed exceptional performance with a 216% revenue growth over Q1 2025, driven by the successful launch of the Motiva platform. The company's minimally invasive platform generated $9.1 million in revenue, indicating strong market acceptance. Gross margin improved by 350 basis points to 70.7%, reflecting operational efficiency and higher-margin product sales. Establishment Labs Holdings Inc (NASDAQ:ESTA) raised its full-year revenue guidance to $266.5 million to $268.5 million, up from the previous range of $264 million to $266 million, demonstrating confidence in continued growth. Despite strong growth, the company remains cautious due to geopolitical uncertainties and is conservative in its business forecasts. SG&A expenses increased by $3.9 million, primarily due to higher sales-related costs and foreign exchange impacts. Cash decreased by $7.5 million during the quarter, driven by investments in the U.S. market, indicating ongoing financial pressures. The company has not yet finalized a long-term agreement with its silicone supplier, Nusil, which could impact future cost structures. The minimally invasive platform, while promising, is still in early stages of adoption in the U.S., and its long-term impact on market share remains uncertain. Warning! GuruFocus has detected 4 Warning Signs with ESTA. Is ESTA fairly valued? Test your thesis with our free DCF calculator. Q: How much of the U.S. growth is attributed to new accounts versus the Preservay launch? A: The U.S. progress has exceeded expectations, driven by expanding the Motiva business and increasing account utilization. Preservay is expected to be a significant future driver due to its patient benefits like minimal anesthesia and quicker recovery. Unidentified_6 Q: How is the minimally invasive platform, particularly Preservay, impacting the traditional Motiva business? A: The minimally invasive platform is complementary to the traditional Motiva business. Preservay and MIA are expanding the market by attracting new patients who were not considering breast augmentation before. This is expected to drive category growth. Unidentified_6 Q: Can Preservay become the standard of care over traditional breast augmentation in the U.S.? A: Minimally invasive procedures like Preservay have the potential to become standard due to their benefits, such as smaller scars and quicker recovery. The innovation with unique implants is beneficial for these procedures, and this is just the starting point for us. Unidentified_6 Q: Has the Preservay launch increased the conversion of accounts that hadn't adopted Motiva? A: While it's early in the U.S. launch, the minimally invasive platform has brought new accounts in Western Europe. We expect a similar trend in the U.S., potentially driving account acquisition. Unidentified_6 Q: What are the macroeconomic impacts, particularly concerning the Middle East and consumer behavior? A: The Middle East represents 5% of total sales, and while there were no orders in Q1, we expect shipments in Q2. Globally, we haven't seen an impact on demand for procedures, and costs like silicone are locked in for the year. Unidentified_6 and Unidentified_12 For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Achieved 45% revenue growth in Q1 2026, driven by a 216% surge in U.S. revenue as the Motiva launch gains significant momentum among high-volume surgeons. Realized the third consecutive quarter of positive adjusted EBITDA, demonstrating operational leverage and a clear path toward becoming cash flow positive by the second half of 2026. Expanded gross margins by 350 basis points to 70.7%, primarily due to the higher-margin U.S. direct business and the premium pricing of the minimally invasive platform. Successfully launched the Preserve minimally invasive platform in the U.S., surpassing the full-year surgeon certification goal within the first quarter due to exceptional demand. Maintained a strong technology moat through a robust IP portfolio and clinical data showing device-related complication rates of less than 1%, significantly lower than industry competitors. A survey of 94 patients showed that 15% were new to the breast augmentation category, suggesting the minimally invasive platform is actively expanding the total addressable market. Strengthened the balance sheet through a debt refinancing with Oaktree, providing enhanced financial flexibility and liquidity to support ongoing commercial expansion. Raised full-year 2026 revenue guidance to a range of $266.5 million to $268.5 million, reflecting strong Q2 weekly order highs in the U.S. market. Increased 2026 revenue expectations for the minimally invasive business to over $35 million, up from the previous $30 million target, based on rapid surgeon adoption. Anticipates U.S. revenue will exceed 30% of total annual revenue in 2026, up from approximately 22% in the prior year. Assumes a transition to cash flow positive status in the second half of 2026, supported by improved working capital efficiency and PIK interest benefits of over $5 million per quarter. Planning for significant future growth drivers including U.S. breast reconstruction approval, the launch of the GEM gluteal solution, and expansion into the Canadian market. Exposure to the Middle East remains limited at less than 5% of total revenue, though management is monitoring potential macro impacts on global demand and freight costs. Secured 2026 silicone supply volumes and pricing with NuSil, with active negotiations underway for a long-term partnership exceeding five years. Expects Q2 cash usage to be higher than Q1 due to a final $4.7 million Benelux acquisition payment and seasonal short-term incentive payouts. Potential inclusion in the Russell 2000 index following the April 30th rank date is expected to increase institutional interest and benchmarking. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management clarified that the minimally invasive platform is complementary; 15% of Preserve patients were not previously considering surgery, indicating market expansion. In international markets, all Mia accounts also offer Preserve, demonstrating a 'good, better, best' portfolio approach that captures different price points and patient goals. U.S. order growth saw a 30% increase in average daily orders since the end of Q4, driven by both new account onboarding and increased utilization from existing surgeons. The Preserve launch is expected to accelerate account acquisition as surgeons seek to offer the latest minimally invasive techniques to meet patient demand. Current year costs are locked in, and long-term negotiations with NuSil are focused on co-development and exclusivity rather than just volume-based pricing. Management expressed high confidence in the 15-year partnership, noting that Establishment Labs is becoming an increasingly valuable customer to the supplier. Current 2026 guidance does not assume a specific timeline for FDA approval of the reconstruction indication, though it represents a doubling of the addressable market. Future approval is expected to further enhance the margin profile as it will be sold through the high-margin U.S. direct sales channel. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

NEW YORK, May 06, 2026--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United States, up 13.3% from Q4 2025 Minimally invasive revenue of $9.1 million for the quarter Gross margin of 70.7% compared to 67.2% in the year-ago period Loss from operations was $6.5 million compared to a loss of $16.9 million in the year-ago period Adjusted EBITDA income of $1.2 million compared to a loss of $12.1 million in the year-ago period Cash use $7.5 million compared to use of $21.2 million in the year-ago period Cash balance of $68.1 million as of March 31, 2026 "Our momentum is accelerating across both the United States and OUS (outside of the U.S.) markets," said Peter Caldini, Chief Executive Officer. "The U.S. launch of our minimally invasive platform is off to a strong start and is contributing meaningfully to our growth; we now expect it to make up at least 13% of 2026 revenue, up from previous guidance. At the same time, we’ve delivered our third consecutive quarter of positive adjusted EBITDA, underscoring the strength of our execution and the operational leverage inherent to this business." "Our first quarter performance gives us confidence to raise our annual guidance," said Sandra Harris, Chief Financial Officer of Establishment Labs. "Our recent refinancing with Oaktree extends our debt maturity and further enhances our financial flexibility. We expect to be free cash flow positive in the second half of the year and are focused on meaningfully increasing earnings per share every year moving forward." First Quarter 2026 Financial Results (Unaudited) Total revenue for the quarter ended March 31, 2026 was $59.9 million, compared to $41.4 million for the same period in 2025, representing a growth of approximately 44.7%, with Motiva U.S. revenue increasing to $19.6 million from $6.2 million in the prior-year period. Gross profit for the first quarter of $42.3 million, or 70.7% of revenue, increased compared to $27.8 million, or 67.2% of revenue, for the same period in 2025. The improvement in gross profit margin was primarily driven by geographic and channel mix. Total operating expenses for the first quarter were $48.8 million, $4.0 million higher compared to $44.8 million in the first quarter of 2025. This represents a 8.9% increase supporting a 44.7% growth of revenue, showing our ability to leverage operating expenses as we scale the business. Net loss for the first quarter was $13.4 million, compared to a net loss of $20.7 million in the year-ago period. Adjusted EBITDA increased by $13.3 million to an income of $1.2 million compared to a loss of $12.1 million in the year-ago period, achieving our third consecutive quarter of positive adjusted EBITDA. The Company’s cash balance on March 31, 2026 was $68.1 million. Fiscal 2026 Outlook The Company raises guidance based on the first-quarter 2026 performance, and expects the following results: Revenue: $266.5 million to $268.5 million, up from our previous range of $264 million to $266 million. Minimally invasive business to exceed $35 million in 2026 up from the previous guidance of $30 million Gross margin: 71.2% to 72.2% Operating expenses: $195 million to $200 million Adjusted EBITDA: Positive every quarter Free cash flow positive in the second half of the year Conference Call and Webcast Information Establishment Labs will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss its financial results. To participate in the conference call, Dial: 877-407-8037 (US & Canada) or +1 201-689-8037 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zen™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com. Non-GAAP Financial Measures To supplement our financial results presented in accordance with GAAP, this release includes the following measures defined by the Securities and Exchange Commission as non-GAAP financial measures: EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP measures used by other companies, limiting the usefulness of the measures for comparison with other companies. EBITDA is defined as net income or loss excluding: (1) interest income and expense; (2) provision for income taxes; and (3) depreciation and amortization. We consider EBITDA useful to an investor in evaluating and facilitating comparisons of our operating performance between periods by removing the impact of our capital structure (primarily interest expense) and asset base (primarily depreciation and amortization) from our operating results. We also present Adjusted EBITDA which includes additional adjustments for items such as other non-cash charges, gains or losses on extinguishment of debt, share-based compensation, contract termination costs, foreign currency gains and losses and restructuring costs. We believe that Adjusted EBITDA provides useful supplemental information to investors regarding our ongoing operating performance that, when considered with net income and EBITDA, is beneficial to an investor's understanding of our performance. We believe disclosure of this information is also useful to investors as it provides insight into the earnings that management uses to make strategic decisions. These non-GAAP financial measures should be considered along with, but not as alternatives to, net income or loss as prescribed by GAAP as a measure of our operating performance. EBITDA and Adjusted EBITDA do not represent cash generated from operating activities under GAAP and should not be considered as alternatives to cash flows from operations or any other operating performance measure prescribed by GAAP. These measures are not measures of our liquidity, nor are indicative of funds available to fund our cash needs. These measurements do not reflect cash expenditures for long-term assets and other items that have been and will be incurred. EBITDA and Adjusted EBITDA may include funds that may not be available for management’s discretionary use due to functional requirements to conserve funds for capital expenditures, property acquisitions, and other commitments and uncertainties. Please see "Reconciliation of EBITDA and Adjusted EBITDA" for a reconciliation of these measures to net income (loss), the most directly comparable financial measure. This release also includes information about our expectations regarding Adjusted EBITDA on a forward-looking basis. We have not provided a reconciliation of such forward-looking Adjusted EBITDA information because a reconciliation of such measure to our expected GAAP net income (loss) on a forward-looking basis is not available without unreasonable efforts. The timing or amount of various reconciling items that would impact the forward-looking expectations for this non-GAAP financial measure are uncertain, depend on various factors and cannot be reasonably predicted. Such unavailable information could be material to our results computed in accordance with U.S. GAAP. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "intends to," "would," "will," "may" or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company's annual report on Form 10-K filed on February 27, 2026, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends. View source version on businesswire.com: https://www.businesswire.com/news/home/20260506890846/en/ Contacts Investor/Media Contact: Malavika William [email protected]

Strong Q1 results and raised outlook: Establishment Labs reported Q1 revenue of $59.9 million and adjusted EBITDA of $1.2 million (third consecutive quarter of positive adjusted EBITDA), with revenue up 45% year-over-year and management raising full-year 2026 revenue guidance to $266.5–$268.5 million (≈26–27% growth). U.S. ramp and minimally invasive momentum: U.S. revenue surged to $19.6 million (up 216% YoY) as the company surpassed 1,700 U.S. accounts; the Preservé minimally invasive platform, launched in the U.S. in March, generated $9.1 million in Q1 and management now expects minimally invasive revenue to exceed $35 million in 2026. Refinancing and path to cash-flow positivity: Cash fell to $68.1 million after U.S. investments, the credit facility was increased to $265 million at an 8.75% rate with PIK options, and management expects to reach cash-flow positive in the second half of 2026 without the need for equity financing. Interested in Establishment Labs Holdings Inc.? Here are five stocks we like better. Establishment Labs (NASDAQ:ESTA) reported first-quarter 2026 revenue of $59.9 million and adjusted EBITDA of $1.2 million, marking what Chief Executive Officer Peter Caldini described as “a strong start to the year.” Revenue increased 45% versus the prior-year period, and the company posted its third consecutive quarter of positive adjusted EBITDA. Caldini said the U.S. business “continued to outperform” with revenue of $19.6 million, up 216% year over year and 13.3% sequentially, despite what management called a seasonally light quarter for breast augmentation and reconstruction. Outside the U.S., the company delivered about 15% growth, and its minimally invasive platform generated $9.1 million in quarterly revenue. → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries Gross margin improved 350 basis points to 70.7% from 67.2% in the first quarter of 2025. CFO Sandra Harris attributed the expansion primarily to “the increasing contribution of our higher margin U.S. business,” as well as the growing impact of the minimally invasive platform, which she said carries higher average selling prices and margins. SG&A expense rose to $43.6 million from $39.7 million a year earlier, driven by variable costs tied to higher sales—“including freight”—foreign exchange impacts, and continued investment in the U.S. business, Harris said. Excluding a one-time item, adjusted SG&A was $41.0 million, or 68.4% of revenue, which Harris said represented about 50 basis points of leverage year over year. R&D spending was $5.2 million, consistent with prior quarters. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches Management emphasized accelerating U.S. adoption as a key driver. Harris noted that U.S. revenue represented 32.7% of total revenue in the quarter, up from 26.8% in the fourth quarter of 2025 and 15% in the first quarter of 2025. Caldini said the company recently surpassed 1,700 accounts in the U.S. and is seeing increased adoption from higher-volume surgeons, with “30% increase in average orders since the end of Q4.” On the call, he clarified that the order-growth comment was specific to the U.S. Establishment Labs officially launched its minimally invasive platform in the U.S. in March, led by Preservé. Caldini said demand was strong enough that, after initially training surgeons at the company’s Costa Rica campus, Establishment Labs began training in the U.S. as well to accelerate certification. The company certified more than 260 U.S. surgeons by the end of the first quarter, exceeding its prior goal of training 200 by the end of 2026, he said. → Tyson Foods' Total Returns: Tasty Treats for Income Investors? Caldini also pointed to early patient data from a survey of 94 Preservé patients three months post-surgery, reporting that 98% said they experienced minimal disruption to daily life and 95% said they were satisfied or extremely satisfied with results. He added that 15% of surveyed patients were new to the category and had not considered breast augmentation until learning about Preservé, while 84% said they were willing to pay a premium for the procedure’s benefits and 99% said they would choose it again. In response to analyst questions, Caldini said the U.S. growth is still primarily driven by base Motiva implant adoption and utilization within accounts, while adding that Preservé is expected to be a significant growth driver over time. He also said that in markets outside the U.S. where both Mia and Preservé are available, the two procedures have been “very complementary,” with Mia positioned as a more premium, more restrictive offering and Preservé described as more “day-to-day” and lower-priced than Mia. Caldini said Preservé has helped bring in new accounts in some of the company’s direct markets in Western Europe, and he expects a similar trend could develop in the U.S. as the launch progresses. Caldini highlighted several planned growth drivers, including expansion into U.S. breast reconstruction, which he said is “equal in size to the breast augmentation market.” He said the company submitted Motiva implants to the FDA for approval in primary and revision breast reconstruction in December 2025 and is progressing through the review process. Harris later said the company has made “no assumptions” about timing of FDA approval for reconstruction in its outlook. On product timing, Caldini said the company has had discussions with the FDA regarding approval requirements for the Motiva Ergonomix2 implant, but he does not see it as “a significant driver for us until probably around 2028.” Mia is not yet available in the U.S., while Preservé has recently been introduced domestically. Following first-quarter performance, management raised full-year 2026 revenue guidance to $266.5 million to $268.5 million, up from $264 million to $266 million. Harris said the updated range implies approximately 26% to 27% growth over 2025. The company expects its business outside the U.S. to grow in the single digits, while the U.S. is expected to exceed 30% of total revenue for the year, up from about 22% last year. For the minimally invasive business, Harris said first-quarter revenue of $9.1 million came in above expectations, and the company now expects minimally invasive revenue to exceed $35 million in 2026, up from its prior $30 million outlook. The company expects full-year gross margin of 71.2% to 72.2%, operating expenses of $195 million to $200 million, and adjusted EBITDA to be positive in each quarter of 2026. Harris added that the company expects second-quarter EBITDA to be approximately double first-quarter levels, even as operating expenses remain elevated due to U.S. investment. Cash and financing were also a focus. Harris said cash decreased $7.5 million during the quarter to $68.1 million, primarily due to investments in the U.S. market. Caldini said the company refinanced its credit facility and expects to reach cash flow positive in the second half of the year, while Harris said the company has “enough cash on hand to reach cash flow positive” and has “no needs or plans to do any type of equity financing.” Harris outlined expected near-term cash usage in the second quarter, including a final $4.7 million payment related to the Benelux acquisition, the timing of short-term incentive payouts, and continued U.S. commercial investments, partially offset by $6 million of proceeds from the recent debt refinancing. She also said the refinancing introduced PIK interest, which she expects to benefit cash performance in the back half of the year, describing “PIK interest of more than $5 million per quarter.” In response to a question on the new debt agreement, Harris said the facility increased from $225 million to $265 million drawn and carries an 8.75% interest rate, with the ability to use PIK. She characterized the net impact as “neutral to slightly up” when considering increased availability of funds, the lower interest rate, and use of PIK. Addressing macro conditions, Caldini said the company has not seen an impact on global procedure demand so far, though it is monitoring the environment. He noted the Middle East represents about 5% of total sales, and the company had no orders from the region in the first quarter but had orders in the system for the second quarter. Harris added that the company is seeing “some initial surcharges on outbound freight” but said it has been able to navigate those costs while holding margins; she also said silicone volumes are locked in under contract through year-end. Separately, Harris said the company believes it is well-positioned to qualify for inclusion in Russell indices based on current market capitalization, noting that April 30 marked the Russell reconstitution rank date, with final membership to be confirmed in the coming months. Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability. The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification. The article "Establishment Labs Q1 Earnings Call Highlights" was originally published by MarketBeat.